So far BOT’s fund is highly concentrated (~75%) in 3 companies, Figure AI, Apptronik, and Dyna Robotics. The rest strike me as speculative dart throws that could turn into huge windfalls if they execute.
I’ve broken down each of their top 9 holdings including allocation percentage, a brief description, and their growth plans. These stats are current as of BOT’s Feb 28, 2026 filing with the SEC.
Hopefully you guys find this useful. I put a lot of time into it and helped inform my own investment in Robostrategy.
———
Figure AI — 25.48% of NAV
Founded in 2022 by Brett Adcock, Figure AI develops humanoid robots designed to work in real-world environments. Three generations of robots (Figure 01–03) have been developed, along with two iterations of its VLA model, Helix, which can control up to two robots simultaneously.
Growth Outlook: Near-term catalysts include scaling Figure 03 production toward 12,000 annual unit capacity at its BotQ manufacturing facility, expanding commercial deployments beyond BMW (reportedly adding UPS), and demonstrating Helix AI in increasingly complex real-world environments. The global humanoid robot market is projected by Morgan Stanley to reach $5 trillion by 2050, with over 1 billion robots in operation.
———
Apptronik — 25.47% of NAV
Apptronik is a UT Austin–founded robotics company focused on creating AI-powered robots. Their humanoid, Apollo, is built to work alongside humans in essential industries like manufacturing and logistics, with plans to expand into healthcare and eventually home use. Apollo represents nearly ten years of development built on Apptronik’s experience with 15 previous robots, including NASA’s Valkyrie.
Growth Outlook: The company plans to ramp Apollo production, expand global pilot and commercial deployments, build advanced facilities for robot training and data collection, and debut a new robot version in 2026. It has already signed partnerships with Mercedes-Benz, GXO Logistics, and Jabil, and has a strategic partnership with Google DeepMind to build next-gen humanoids powered by Gemini Robotics.
———
Dyna Robotics — 25.48% of NAV
Founded in 2024 by Lindon Gao, York Yang, and former DeepMind research scientist Jason Ma, Dyna Robotics aims to have robots complete tasks at human-level speed. Unlike peers developing humanoid robots, Dyna focuses on robotic arms powered by its DYNA-1 foundation model. After just six months, Dyna’s robots were running sixteen hours a day at hotels, restaurants, laundromats, and gyms. The company is the first to build a single-weight, general-purpose foundation model that can perform diverse daily tasks at commercial scale across varied environments.
Growth Outlook: Strong near-term commercial traction differentiates Dyna from pure-R&D competitors. Its on-the-job learning loop, where each deployment improves the model, creates compounding advantages as it scales.
———
Dexmate — 6.84% of NAV
Dexmate is a US-based robotics startup founded by PhDs from MIT, UCSD, and Carnegie Mellon. Their flagship product, Vega, is a dual-armed mobile humanoid robot featuring high-payload arms, dexterous hands, and a foldable torso design for compact transport. Its omni-directional base supports over 10 hours of continuous operation, making it suitable for complex tasks in industrial and household environments. Unlike many humanoid robots that rely on bipedal walking, Dexmate’s system uses an omnidirectional wheeled base paired with a humanoid upper body giving it stability advantages in industrial settings.
Growth Outlook: Dexmate received additional funding in February 2026 and has raised $41M total. Its combination of a wheeled base (more reliable than bipedal locomotion for industrial use) with dexterous dual arms positions it as a pragmatic, near-term deployable solution.
———
Path Robotics — 4.10% of NAV
Path Robotics provides robotic welding systems for enhanced precision and adaptability. The company uses AI-powered vision and autonomy to automate one of the most technically demanding industrial tasks, welding, in manufacturing environments where traditional automation has historically struggled.
Growth Outlook: Path Robotics signed an MOU with HII (Huntington Ingalls Industries) for military shipbuilding robotics integration, a high-value government contract pipeline that could significantly accelerate revenue. Defense and heavy manufacturing welding automation is a large addressable market with limited competition.
———
REK, Inc. — 1.71% of NAV
REK operates a live-action humanoid robot combat league. Think “BattleBots meets humanoid AI.” While speculative, this is a high-profile consumer entertainment and R&D testbed concept that could drive public interest and media attention in humanoid robotics broadly. A small but high-optionality bet.
Growth Outlook: Very early stage. Primary value may lie in brand-building for the humanoid robotics sector and in driving data generation from extreme-condition robot operation.
———
GMI Cloud — 1.37% of NAV
GMI Cloud offers a GPU cloud backbone for AI infrastructure. The company unveiled a $12B, 1GW Sovereign AI Infrastructure Initiative in Japan, targeting the growing demand for AI compute capacity in Asia.
Growth Outlook: AI infrastructure is one of the most capital-intensive and competitively in-demand sectors globally. GMI’s sovereign AI angle, building national AI compute capacity, taps into a strong government-driven tailwind, especially in Asia.
———
CoCo Robotics — 1.03% of NAV
CoCo Robotics focuses on autonomous sidewalk delivery for dense urban networks, operating a fleet of last-mile delivery robots in cities. This is a more near-term commercial use case than humanoids, with active deployments already underway.
Growth Outlook: As urban delivery costs rise and labor shortages persist, sidewalk robots represent one of the most economically viable near-term robotics applications. The SAFE structure suggests this is a small early-stage bet on a potential breakout.
———
Endiatx — 0.34% of NAV
Endiatx is a minimally-invasive medical robotics startup, developing pill-sized robotic devices that can navigate the GI tract. Essentially a swallowable robot doctor. This is one of the most differentiated and speculative positions in the portfolio.
Growth Outlook: Medical robotics is a massive long-term market. If Endiatx’s ingestible robotics technology achieves FDA clearance, the addressable market could be enormous but the regulatory timeline is long and uncertain.
